Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 14;42(25):126119.
doi: 10.1016/j.vaccine.2024.07.020. Epub 2024 Jul 12.

Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants

Florencia A Bonnin  1 , Laura B Talarico  2 , Fausto M Ferolla  3 , Patricio L Acosta  4 , Emily Phung  5 , Azad Kumar  5 , Analía Toledano  6 , Ana Caratozzolo  6 , Pablo Neira  7 , Normando Mascardi  8 , Daniela Satragno  8 , María M Contrini  3 , Barney S Graham  5 , Tracy J Ruckwardt  5 , Eduardo L López  9 ; GUTI Respiratory Infections Network
Affiliations

Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants

Florencia A Bonnin et al. Vaccine. .

Abstract

Background: Humoral immune response against the pre-fusion (pre-F) conformation of respiratory syncytial virus (RSV) F protein has been proposed to play a protective role against infection. An RSV pre-F maternal vaccine has been recently approved in several countries to protect young infants against RSV. We aimed to assess serum IgG titers against the pre-F and post-F conformations of RSV F protein and their association with life-threatening RSV disease (LTD) in previously healthy infants.

Methods: A prospective cohort study including hospitalized infants <12 months with a first RSV infection was conducted during 2017-2019. Patients with LTD required intensive care and mechanical respiratory assistance. RSV pre-F exclusive and post-F antibody responses were determined by post-F competition and non-competition immunoassays, respectively, and neutralizing activity was measured by plaque reduction neutralization test.

Results: Fifty-eight patients were included; the median age was 3.5 months and 41 % were females. Fifteen patients developed LTD. RSV F-specific antibody titers positively correlated with neutralizing antibody titers in acute and convalescent phases but, importantly, they did not associate with LTD. Acute RSV pre-F exclusive and post-F IgG titers negatively correlated with patient age (P = 0.0007 and P < 0.0001), while a positive correlation was observed between the fold changes in RSV F-specific antibody titers between convalescent and acute phase and patient age (P = 0.0014 and P < 0.0001). Infants ≤2 months exhibited significantly lower fold-changes in RSV F-specific and neutralizing antibody titers between convalescence and acute phase than older infants. Additionally, acute RSV antibody titers showed no correlation with nasal RSV load and, furthermore, nasal viral load was not associated with the development of LTD.

Conclusions: This study highlights that protection against life-threatening RSV disease is not necessarily antibody-dependent. Further characterization of the immune response against RSV and its role in protection against severe disease is important for the development of the safest possible preventive strategies.

Keywords: Antibody response; Life-threatening respiratory syncytial virus disease; Neutralizing activity; Post-fusion protein; Pre-fusion protein; Respiratory syncytial virus; Severity.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Fausto Martin Ferolla reports financial support was provided by Thrasher Research Fund, United States. Eduardo Luis Lopez reports financial support was provided by Fundacion Argentina de Infectologia Pediatrica. Barney S Graham has patent #WO2014160463A1 Prefusion RSV F proteins and their use licensed to Assignee. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017;390:946–58. 10.1016/S0140-6736(17)30938-8. - DOI - PMC - PubMed
    1. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 2022;399:2047–64. 10.1016/S0140-6736(22)00478-0. - DOI - PMC - PubMed
    1. Moisi JC, Gatakaa H, Berkley JA, Maitland K, Mturi N, Newton CR, et al. Excess child mortality after discharge from hospital in Kilifi, Kenya: a retrospective cohort analysis. Bull World Health Organ 2011;89:725–32, 32A. 10.2471/BLT.11.089235. - DOI - PMC - PubMed
    1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010;375:1545–55. 10.1016/S0140-6736(10)60206-1. - DOI - PMC - PubMed
    1. Carroll KN, Hartert TV. The impact of respiratory viral infection on wheezing illnesses and asthma exacerbations. Immunol Allergy Clin North Am 2008;28:539–61, viii. 10.1016/j.iac.2008.03.001. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources